COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
Share  
Tweet  
@CovidAnalysis
11/20
Positive
POSITIVE
Late
Garibaldi et al., medRxiv, doi:10.1101/2020.11.19.20234153 (Preprint)
death, ↓20.0%, p=0.44 Effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19
Retrospective 303 remdesivir patients and 303 matched controls showing significantly faster clinical improvement, and lower (but not statistically significant) mortality.
11/3
Positive
POSITIVE
Late
Flisiak et al., medRxiv, doi:10.1101/2020.10.30.20215301 (Preprint)
death, ↓48.9%, p=0.18 Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study
Retrospective study comparing 122 remdesivir patients and 211 lopinavir/ritonavir patients, showing higher rates of clinical improvement with remdesivir and lower mortality (not statistically significant).
10/20
Positive
POSITIVE
Late
Solh et al., medRxiv, doi:10.1101/2020.10.16.20214130 (Preprint)
death, ↓47.0%, p<0.001 Clinical course and outcome of COVID-19 acute respiratory distress syndrome: data from a national repository
Retrospective database analysis of 7,816 Veterans Affairs hospitalized patients showing 47% reduction in progression from ARDS to mortality.
10/15
Negative
NEGATIVE
Late
SOLIDARITY Trial Consortium, medRxiv, doi:10.1101/2020.10.15.20209817 (Preprint)
death, ↓5.0%, p=0.53 Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
WHO SOLIDARITY open-label RCT with 2,750 very late stage (76% on oxygen/ventilation) Remdesivir patients, mortality relative risk RR 0.95 [0.81-1.11], p=0.50. Non-ventilated patients show a greater benefit, RR 0.86 [0.72-1.04], p = 0.13.
10/8
Positive
POSITIVE
Late
Beigel et al., NEJM, doi:10.1056/NEJMoa2007764 (Peer Reviewed)
death, ↓27.0%, p=0.07 Remdesivir for the Treatment of Covid-19 — Final Report
RCT 1,062 hospitalized patients showing faster recovery time with treatment, median 10 days vs. 15 days for placebo, rate ratio for recovery 1.29, p<0.001. Day 29 mortality was 11.4% with remdesivir and 15.2% with placebo, hazard ratio H..
8/21
Positive
POSITIVE
Late
Spinner et al., JAMA, doi:10.1001/jama.2020.16349 (Peer Reviewed)
death, ↓34.9%, p=0.50 Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19A Randomized Clinical Trial
Late stage (median 8 days from symptom onset) RCT 584 patients with moderate COVID-19 showing (non-statistically significant) lower mortality. 5-day remdesivir had significantly higher odds of a better clinical status distribution on the..
6/29
Meta
META
Late
Zhu et al., medRxiv, doi:10.1101/2020.06.22.20136531 (Peer Reviewed) (meta analysis)
death, ↓36.0%, p=0.02 Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials
Meta analysis of Beigel and Wang RCTs showing remdesivir significantly decreased mortality (8.18% vs. 12.70%, RR 0.64 [0.44-0.92], p = 0.175).
5/27
Inconc.
INCONC.
Late
Goldman et al., NEJM, doi:10.1056/NEJMoa2015301 (Peer Reviewed)
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
RCT of remdesivir for 5 or 10 days with no placebo control group, showing no significant differences between 5 and 10 day treatment. NCT04292899
6/29
Inconc.
INCONC.
Late
Wang et al., Lancet, doi:10.1016/S0140-6736(20)31022-9 (Peer Reviewed)
death, ↑8.6%, p=1.00 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Small RCT with 237 hospitalized patients in China with severe COVID-19, not showing statistically significant benefits. 158 treatment patients and 79 control patients. While too small for significance, the subgroup treated within 10 days..


Please send us corrections, updates, comments.
Submit